Fortress Biotech, Inc. (FBIO)
2.77
-0.03
(-1.07%)
USD |
NASDAQ |
Aug 28, 16:00
2.78
+0.01
(+0.36%)
After-Hours: 20:00
Fortress Biotech Free Cash Flow : 120.28M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 120.28M |
| March 31, 2026 | 152.08M |
| December 31, 2025 | -71.34M |
| September 30, 2025 | -30.14M |
| June 30, 2025 | -95.09M |
| March 31, 2025 | -89.37M |
| December 31, 2024 | -95.19M |
| September 30, 2024 | -153.28M |
| June 30, 2024 | -100.00M |
| March 31, 2024 | -118.49M |
| December 31, 2023 | -136.32M |
| September 30, 2023 | -149.56M |
| June 30, 2023 | -196.19M |
| March 31, 2023 | -197.60M |
| December 31, 2022 | -202.58M |
| September 30, 2022 | -194.45M |
| June 30, 2022 | -159.78M |
| March 31, 2022 | -158.94M |
| December 31, 2021 | -132.89M |
| September 30, 2021 | -114.83M |
| June 30, 2021 | -111.74M |
| March 31, 2021 | -89.32M |
| December 31, 2020 | -90.85M |
| September 30, 2020 | -98.54M |
| June 30, 2020 | -91.90M |
| Date | Value |
|---|---|
| March 31, 2020 | -102.40M |
| December 31, 2019 | -104.36M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| September 30, 2018 | -112.57M |
| June 30, 2018 | -112.42M |
| March 31, 2018 | -106.38M |
| December 31, 2017 | -91.25M |
| September 30, 2017 | -82.28M |
| June 30, 2017 | -65.81M |
| March 31, 2017 | -55.52M |
| December 31, 2016 | -56.14M |
| September 30, 2016 | -44.82M |
| June 30, 2016 | -40.12M |
| March 31, 2016 | -36.39M |
| December 31, 2015 | -32.31M |
| September 30, 2015 | -28.06M |
| June 30, 2015 | -23.80M |
| March 31, 2015 | -19.95M |
| December 31, 2014 | -15.94M |
| September 30, 2014 | -19.39M |
| June 30, 2014 | -24.21M |
| March 31, 2014 | -28.27M |
| December 31, 2013 | -29.69M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Inovio Pharmaceuticals, Inc. | -80.78M |
| Ironwood Pharmaceuticals, Inc. | 185.55M |
| Kura Oncology, Inc. | -117.43M |
| Spero Therapeutics, Inc. | 19.58M |
| Cue Biopharma, Inc. | -50.17M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -59.28M |
| Cash from Investing (Quarterly) | -0.079M |
| Cash from Financing (Quarterly) | 0.091M |
| Free Cash Flow Per Share (Quarterly) | -1.867 |
| Free Cash Flow to Equity (Quarterly) | -59.04M |
| Free Cash Flow to Firm (Quarterly) | -58.39M |
| Free Cash Flow Yield | 129.0% |